NUVB Share Price Performance
US$4.40
2.44 (124.49%)
61.3% undervalued intrinsic discount
US$11.38
Fair Value
Price US$4.40
Vestra US$11.38
AnalystConsensusTarget US$10.25
AnalystLowTarget US$8.00
Fair ValueUS$11.38
Share Pricen/a
Nuvation Bio Inc. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 37 Fair Values set on narratives written by author
NUVB Community Narratives
VE
Fair Value US$11.38 61.3% undervalued intrinsic discount
Nuvation Bio Inc. (NUVB): Transitioning from Biotech Pipeline to Commercial Contender in 2026.
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$10.25 57.1% undervalued intrinsic discount
Emerging Glioma Therapy And Lung Cancer Expansion Will Transform Long Term Oncology Franchise
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value US$8 45.0% undervalued intrinsic discount
RNA Testing And Glioma Program Will Shape Long Term Prospects Despite Near Term Uncertainty
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Nuvation Bio Inc. (NUVB): Transitioning from Biotech Pipeline to Commercial Contender in 2026.
Nuvation Bio (NUVB) is navigating a high-stakes transition into a commercial-stage oncology firm, with its stock trading at $4.74 as of the March 4, 2026, afternoon session. The shares saw a notable 8.60% recovery today, partially reclaiming ground after a staggering 25.34% drop on March 3rd following its latest financial disclosures.Read more
41
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
RNA Testing And Glioma Program Will Shape Long Term Prospects Despite Near Term Uncertainty
Catalysts About Nuvation Bio Nuvation Bio is an oncology company focused on targeted therapies for specific genetic drivers of cancer. What are the underlying business or industry changes driving this perspective?Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$8
45.0% undervalued intrinsic discount
Fair Value
Profit Margin
20.87%
Future PE
53.27x
Price in 2029
US$9.79
ROS1 Lung Cancer Leadership And Glioma Opportunity Will Transform Long Term Oncology Impact
Catalysts About Nuvation Bio Nuvation Bio is an oncology focused biopharmaceutical company developing and commercializing targeted therapies for difficult to treat cancers. What are the underlying business or industry changes driving this perspective?Read more
59
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$16.8
73.8% undervalued intrinsic discount
Fair Value
Profit Margin
7.28%
Future PE
192.18x
Price in 2028
US$20.55
Emerging Glioma Therapy And Lung Cancer Expansion Will Transform Long Term Oncology Franchise
Catalysts About Nuvation Bio Nuvation Bio is an oncology focused biopharmaceutical company developing and commercializing targeted therapies for difficult to treat cancers. What are the underlying business or industry changes driving this perspective?Read more
117
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
US$10.25
57.1% undervalued intrinsic discount
Fair Value
Profit Margin
0.012%
Future PE
853.58x
Price in 2028
US$0.13
Trending Discussion
Recently Updated Narratives
VE
Nuvation Bio Inc. (NUVB): Transitioning from Biotech Pipeline to Commercial Contender in 2026.
Fair Value: US$11.38 61.3% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RNA Testing And Glioma Program Will Shape Long Term Prospects Despite Near Term Uncertainty
Fair Value: US$8 45.0% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ROS1 Lung Cancer Leadership And Glioma Opportunity Will Transform Long Term Oncology Impact
Fair Value: US$16.8 73.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nuvation Bio Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.60
- 85.22%
- -325.31%
- 20.4%
About NUVB
- Founded
- 2018
- Employees
- 298
- CEO
- WebsiteView website
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
